Inflammation Testing Prompts Care Changes Leading to Significantly Lower Levels in Patients with Increased Cardiovascular Risk Due to Diabetes or Pre-Diabetes

BOCA RATON, Fla., March 27, 2018 — New research from MDVIP and Cleveland HeartLab finds that patients with diabetes, pre-diabetes or no evidence of diabetes whose physicians ordered myeloperoxidase (MPO) inflammation testing achieved sharp reductions in MPO levels over five years.